Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
Hepatology. 2012 Sep;56(3):1004-14. doi: 10.1002/hep.25745. Epub 2012 Jul 12.
Hepatocellular carcinoma (HCC) exhibits cellular heterogeneity and embryonic stem-cell-related genes are preferentially overexpressed in a fraction of cancer cells of poorly differentiated tumors. However, it is not known whether or how these cancer cells contribute to tumor initiation and progression. Here, our data showed that increased expression of pluripotency transcription factor Nanog in cancer cells correlates with a worse clinical outcome in HCC. Using the Nanog promoter as a reporter system, we could successfully isolate a small subpopulation of Nanog-positive cells. We demonstrate that Nanog-positive cells exhibited enhanced ability of self-renewal, clonogenicity, and initiation of tumors, which are consistent with crucial hallmarks in the definition of cancer stem cells (CSCs). Nanog(Pos) CSCs could differentiate into mature cancer cells in in vitro and in vivo conditions. In addition, we found that Nanog(Pos) CSCs exhibited resistance to therapeutic agents (e.g., sorafenib and cisplatin) and have a high capacity for tumor invasion and metastasis. Knock-down expression of Nanog in Nanog(Pos) CSCs could decrease self-renewal accompanied with decreased expression of stem-cell-related genes and increased expression of mature hepatocyte-related genes. Overexpression of Nanog in Nanog(Neg) cells could restore self-renewal. Furthermore, we found that insulin-like growth factor (IGF)2 and IGF receptor (IGF1R) were up-regulated in Nanog(Pos) CSCs. Knock-down expression of Nanog in Nanog(Pos) CSCs inhibited the expression of IGF1R, and overexpression of Nanog in Nanog(Neg) cells increased the expression of IGF1R. A specific inhibitor of IGF1R signaling could significantly inhibit self-renewal and Nanog expression, indicating that IGF1R signaling participated in Nanog-mediated self-renewal.
These data indicate that Nanog could be a novel biomarker for CSCs in HCC, and that Nanog could play a crucial role in maintaining the self-renewal of CSCs through the IGF1R-signaling pathway.
肝细胞癌 (HCC) 表现出细胞异质性,胚胎干细胞相关基因在分化不良肿瘤的一部分癌细胞中优先过表达。然而,尚不清楚这些癌细胞是否以及如何促进肿瘤的起始和进展。在这里,我们的数据表明,癌细胞中多能转录因子 Nanog 的表达增加与 HCC 的临床预后较差相关。使用 Nanog 启动子作为报告系统,我们能够成功分离出一小部分 Nanog 阳性细胞。我们证明,Nanog 阳性细胞表现出增强的自我更新、克隆形成和肿瘤起始能力,这与癌症干细胞 (CSC) 定义中的关键特征一致。Nanog(Pos) CSCs 可以在体外和体内条件下分化为成熟的癌细胞。此外,我们发现 Nanog(Pos) CSCs 对治疗药物(例如索拉非尼和顺铂)具有耐药性,并且具有高的肿瘤侵袭和转移能力。Nanog(Pos) CSCs 中 Nanog 的敲低表达可降低自我更新能力,同时降低干细胞相关基因的表达,增加成熟肝细胞相关基因的表达。Nanog 在 Nanog(Neg) 细胞中的过表达可恢复自我更新。此外,我们发现胰岛素样生长因子 (IGF)2 和 IGF 受体 (IGF1R) 在 Nanog(Pos) CSCs 中上调。Nanog(Pos) CSCs 中 Nanog 的敲低表达抑制 IGF1R 的表达,而 Nanog 在 Nanog(Neg) 细胞中的过表达增加 IGF1R 的表达。IGF1R 信号通路的特异性抑制剂可显著抑制自我更新和 Nanog 表达,表明 IGF1R 信号通路参与了 Nanog 介导的自我更新。
这些数据表明,Nanog 可能是 HCC 中 CSCs 的新型生物标志物,并且 Nanog 通过 IGF1R 信号通路在维持 CSCs 的自我更新中发挥关键作用。